ABUS (Arbutus Biopharma) YoY EBITDA Growth: -300.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABUS Arbutus Biopharma Corp ABUS
53 GF Score
Price $4.79
GF Value $49.64
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Arbutus Biopharma YoY EBITDA Growth?

Arbutus Biopharma ABUS -3.62% 53 YoY EBITDA Growth is -300.00% as of Jun. 2026. GuruFocus rates ABUS with a GF Score™ of 53/100 and a GF Value™ of $49.64 (Possible Value Trap). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Arbutus Biopharma's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -300.00%.

Arbutus Biopharma's EBITDA per Share for the three months ended in Jun. 2026 was $-0.03.

Arbutus Biopharma YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma YoY EBITDA Growth Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.55 39.17 -4.39 13.79 53.39

Arbutus Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.62 60.78 70.31 784.25 -300.00
ABUS
53GF Score
Arbutus Biopharma Corp ABUS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Arbutus Biopharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.172--0.369)/ | -0.369 |
=53.39 %

Arbutus Biopharma's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.026-0.013)/ | 0.013 |
=-300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -300.00% mean?
Arbutus Biopharma (ABUS) has a YoY EBITDA Growth of -300.00% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's YoY EBITDA Growth too high?
Arbutus Biopharma's current YoY EBITDA Growth is -300.00%. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's YoY EBITDA Growth compare to TBPH and ANNX?
Arbutus Biopharma's YoY EBITDA Growth of -300.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Arbutus Biopharma and its competitors. Arbutus Biopharma's current YoY EBITDA Growth is -300.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $49.64, compared to a current price of $4.79 — trading 90.4% below its estimated fair value. The current YoY EBITDA Growth is -300.00%. Arbutus Biopharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current YoY EBITDA Growth is -300.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.79 is trading 90.4% below its estimated GF Value™ of $49.64. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • YoY EBITDA Growth: -300.00%
  • GF Value™: $49.64 vs. price of $4.79 (90.4% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for ABUS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price
$49.64
GF Value